Platelet-derived growth factor receptor as a prognostic marker and a therapeutic target for imatinib mesylate therapy in osteosarcoma. - Wikidata - wikimedia - TriplyDB

Platelet-derived growth factor receptor as a prognostic marker and a therapeutic target for imatinib mesylate therapy in osteosarcoma.

Platelet-derived growth factor receptor as a prognostic marker and a therapeutic target for imatinib mesylate therapy in osteosarcoma.

http://www.wikidata.org/entity/Q37109503

about

Present Advances and Future Perspectives of Molecular Targeted Therapy for Osteosarcoma Chemotherapy- and irradiation-induced bone loss in adults with solid tumors A summary of the osteosarcoma banking efforts: a report from the Children's Oncology Group and the QuadW Foundation Core-shell hydrogel particles harvest, concentrate and preserve labile low abundance biomarkers Imatinib mesylate exerts anti-proliferative effects on osteosarcoma cells and inhibits the tumour growth in immunocompetent murine models Exploring targeted therapy of osteosarcoma using proteomics data Platelet-derived growth factor receptor/platelet-derived growth factor (PDGFR/PDGF) system is a prognostic and treatment response biomarker with multifarious therapeutic targets in cancers.Platelet-derived growth factor-B normalizes micromorphology and vessel function in vascular endothelial growth factor-A-induced squamous cell carcinomas Nanoparticle technology: addressing the fundamental roadblocks to protein biomarker discovery What are the factors that affect survival and relapse after local recurrence of osteosarcoma?miR-155 inhibitor reduces the proliferation and migration in osteosarcoma MG-63 cells Targeting the PDGF signaling pathway in tumor treatment A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study.Platelets promote osteosarcoma cell growth through activation of the platelet-derived growth factor receptor-Akt signaling axis.Prognostic significance of angiogenesis and angiogenic growth factors in nonsmall cell lung cancer Does expression of glucose transporter protein-1 relate to prognosis and angiogenesis in osteosarcoma?Bone Sarcomas in Pediatrics: Progress in Our Understanding of Tumor Biology and Implications for Therapy.Synergistic antiproliferative effect of imatinib and adriamycin in platelet-derived growth factor receptor-expressing osteosarcoma cells.Elimination of human lung cancer stem cells through targeting of the stem cell factor-c-kit autocrine signaling loop Molecular profiling of childhood cancer: Biomarkers and novel therapies Personalized comprehensive molecular profiling of high risk osteosarcoma: Implications and limitations for precision medicine FOXO1 inhibits osteosarcoma oncogenesis via Wnt/β-catenin pathway suppression.Primary intracranial soft tissue sarcomas in children, adolescents, and young adults: single institution experience and review of the literature.Immune infiltration and PD-L1 expression in the tumor microenvironment are prognostic in osteosarcoma HHLA2, a member of the B7 family, is expressed in human osteosarcoma and is associated with metastases and worse survival Prognostic markers in osteosarcoma.Of dogs and men: comparative biology as a tool for the discovery of novel biomarkers and drug development targets in osteosarcoma.Targeted therapy in bone and soft tissue sarcoma in children and adolescents.E3 ubiquitin ligase-mediated regulation of bone formation and tumorigenesis.Drugs targeting the bone microenvironment: new therapeutic tools in Ewing's sarcoma?Current therapeutic strategies and novel approaches in osteosarcoma.Targeted therapies for bone sarcomas.Platelet-Derived Growth Factor (PDGF)/PDGF Receptors (PDGFR) Axis as Target for Antitumor and Antiangiogenic Therapy.Anti-angiogenesis target therapy for advanced osteosarcoma (Review).Cell surface receptor expression patterns in osteosarcoma.Ligand-dependent platelet-derived growth factor receptor (PDGFR)-alpha activation sensitizes rare lung cancer and sarcoma cells to PDGFR kinase inhibitors.Bone sarcomas: from biology to targeted therapies.High expression of PDGFR-β in prostate cancer stroma is independently associated with clinical and biochemical prostate cancer recurrence Protein kinase C epsilon and genetic networks in osteosarcoma metastasis.Analysis of genomic mutation and immunohistochemistry of platelet-derived growth factor receptors in canine vascular tumours.

P2860

Q26750631-07A6C8B4-F68E-40CD-B0C8-623521BF01C5 Q28084019-CE8163D5-5F94-4F3E-8E69-BC14A9650570 Q28386370-E15327A4-F3C1-4C53-8EA8-C2C90658D45F Q28474977-B62BF262-38CF-4AB6-AD2B-5752CD748CF0 Q28540520-998585EE-6198-4F27-B91C-95F3BF8A6927 Q28817274-8FAA5DCB-595F-40B0-AD3C-07B636D0EB97 Q30250273-BA9678AC-5225-45DD-B832-DABE0A1FC8F1 Q33597254-D7203DC4-57EC-4452-8D6D-8CBDDF7D3AB8 Q33862871-6949E213-4E45-47A2-99EE-69328AB0F470 Q34161337-71D51030-2ADB-47CF-B297-E79DBF7CE2BF Q34292411-3A3393F0-A2A2-425F-B0F2-FDDD9BD32C7F Q34393461-DD9772AD-68F3-4C2E-A54D-DF0C60B4BB43 Q34628840-68DD8CE7-5CE5-455C-BE62-B59FF7C5DB0D Q35051665-86812173-6F63-4AB6-86B8-3D3E3085A9B8 Q35177011-530049AF-208C-478B-AEAD-F90619277B5A Q35335157-800EE56E-4419-4EA8-9B29-F831736129A2 Q35894540-761023AE-3EB0-402F-804A-A3706FFE9484 Q35904214-CB0FEC74-B781-4509-AD90-6866C72AE3BF Q36067817-AD146322-3886-463A-8B29-BADFDBEF44AA Q36250783-3C27C9C5-DBBA-4B1B-8531-8887D0AD9279 Q36562114-92FAA07E-5BDD-40BF-AB04-13300ED4B652 Q36620774-2BBDEF9C-DFA8-4BA9-AA8C-193A3CAEEE70 Q36924325-FDAD8BA5-360A-45A9-8D35-718F2A6CF086 Q37125088-19AFEAB7-C1BD-451E-89B7-42E6BDE9217C Q37181493-E5495A67-157B-4290-8541-1D46F857D72F Q37687395-FCAB7746-92EE-4263-B67D-70E6CF8ACD0F Q37944599-CFF0715A-6E86-4100-BFDC-AD5C213D7A45 Q37981129-21AABA9A-49E4-4341-9156-9D072E9E9396 Q38074797-07BD7DF5-6E8F-4909-8ACF-9AB803C4E597 Q38129954-C2E7BBCB-BC24-4076-8456-FD8F9E58740A Q38161735-AF332D04-0D29-4B30-AB58-582DF64B2F4C Q38178277-5FEFB14F-B592-41C8-B8FD-34E6635A6D1A Q38974204-C425A4A5-F213-40C5-AA81-ADAB1B182D8C Q39401628-AFB6E55F-42F6-4AD8-941E-269326517CED Q39507656-DD610BB2-D05B-468F-B7DA-1B323064A2E2 Q39861042-EA4E64EF-7B71-4513-9553-F510195899A5 Q41923624-0DA9A23C-3435-4C15-8803-10D2FBC6B569 Q41967756-AC890401-5075-4440-8B46-686718BAF7FA Q42265507-A7C799F9-024C-413F-BF15-60EBA3B215FD Q44195449-79F5F5EE-1886-40CF-9A92-262E1D54100E

P2860

Platelet-derived growth factor receptor as a prognostic marker and a therapeutic target for imatinib mesylate therapy in osteosarcoma.

http://www.wikidata.org/entity/Q37109503

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on May 2008

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Platelet-derived growth factor ...... ylate therapy in osteosarcoma.

@en

Platelet-derived growth factor ...... ylate therapy in osteosarcoma.

@nl

type

label

Platelet-derived growth factor ...... ylate therapy in osteosarcoma.

@en

Platelet-derived growth factor ...... ylate therapy in osteosarcoma.

@nl

prefLabel

Platelet-derived growth factor ...... ylate therapy in osteosarcoma.

@en

Platelet-derived growth factor ...... ylate therapy in osteosarcoma.

@nl

P1433

Q37109503-DEFF1B26-9105-4035-831C-A1F04A075511

P1476

Q37109503-2E2BDAB4-8D59-4C4A-B228-6BD039DC9BA0

P2093

Q37109503-29A4206B-7E12-4A34-9B62-577BCCA6854A

Q37109503-2AC1A8E4-E970-4646-81EB-91B9FAD70000

Q37109503-4A599938-0797-4692-AA99-06D5A5601816

Q37109503-5982CD6C-5F4E-4B58-967A-4741BEF4D611

Q37109503-5BE5523B-4AC7-424F-9781-C2EA5BD78C17

Q37109503-6D819951-E261-451B-BCBE-10042CC7C2F5

Q37109503-ABE8F1B1-E231-419A-A85C-2CBB612BE854

Q37109503-D8C6A905-23F4-4AA3-9360-B7049956237B

Q37109503-D997076B-5DE5-49A3-BE98-F72EBFE19323

Q37109503-E1265139-AC73-4999-826E-C6F8452809B2

P2860

Q37109503-19214D5D-DD60-4748-AB53-3101BA63424D

Q37109503-1E49D05A-F226-4359-A05F-35F1CFF5F54C

Q37109503-310AE4E8-A51B-4FF4-86B3-0C54535D33C5

Q37109503-3E7C39E0-08B5-4954-BF68-00602CD5E310

Q37109503-4631CA25-10DD-494C-BB58-C98567438BFD

Q37109503-9EC9B51B-F04A-4BAE-98F3-50C94C63BED6

Q37109503-AB2DEFA4-DF76-4BE5-9A2E-793B6D85B3F6

Q37109503-C4F7CC8A-B88D-41B1-AE44-E41E2A80D55C

Q37109503-E2400CB0-A380-4A90-9A13-B7D38F370E39

Q37109503-F3FA6308-9645-42EC-924B-C0B05274A814

P304

Q37109503-70DDE2C0-0B5C-4A33-8472-F2A9D19FDDFF

P31

Q37109503-B4388A23-B494-430B-B0C4-32FE5340C727

P356

Q37109503-77EE7611-6225-417F-BAD1-A8709C727471

P407

Q37109503-6D9D54A0-1721-4489-9DD2-B59D19E6A284

P433

Q37109503-0A8B190D-6797-49F6-8290-DDBE22FD12C8

P478

Q37109503-2953101D-6991-4AA3-ABEA-BDBDE72846BC

P577

Q37109503-99DB1BBE-9F01-4E3A-BF1C-FA7C4A511567

P5875

Q37109503-B3849A1E-B889-43E6-B8D2-63354DAF488E

P698

Q37109503-9DEEA5E4-E3F5-4ABC-BBD0-4FF437984110

P356

P1433

P1476

Platelet-derived growth factor ...... ylate therapy in osteosarcoma.

@en

P2093

Andrew G Huvos

http://www.w3.org/2001/XMLSchema#string

Cristina R Antonescu

http://www.w3.org/2001/XMLSchema#string

Han-Soo Kim

http://www.w3.org/2001/XMLSchema#string

Jeremy Rosenblum

http://www.w3.org/2001/XMLSchema#string

John H Healey

http://www.w3.org/2001/XMLSchema#string

Paul A Meyers

http://www.w3.org/2001/XMLSchema#string

Rebecca Sowers

http://www.w3.org/2001/XMLSchema#string

Richard Gorlick

http://www.w3.org/2001/XMLSchema#string

Sajida Piperdi

http://www.w3.org/2001/XMLSchema#string

Tadahiko Kubo

http://www.w3.org/2001/XMLSchema#string

P2860

Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells.

RETRACTED: Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class.

Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate.

Neoadjuvant chemotherapy for osteosarcoma of the extremity: long-term results of the Rizzoli's 4th protocol.

Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225.

Beta-platelet-derived growth factor receptor mediates motility and growth of Ewing's sarcoma cells.

Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-alpha.

P304

2119-2129

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/CNCR.23437

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

112

http://www.w3.org/2001/XMLSchema#string

P577

2008-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5513156

http://www.w3.org/2001/XMLSchema#string

P698

18338812

http://www.w3.org/2001/XMLSchema#string